P
PsilocybinLabs - $0.50 Share Offering · Northward Capital
Private Placement Subscription Portal
Live · accepting subscriptions
Offering · NI 45-106 Private Placement

A subscription in 1210954 B.C. Ltd. (PsilocybinLabs)

Common shares offered at $0.50 per Common share to accredited investors and qualifying offerees.

Capital raised · this round
41.6% / target
CA$1,247,500
/ CA$3,000,000 target
Subscribers
38
Avg. ticket
$32.8K
Unit price
$0.50CAD
Security
Common share
Min subscription
100shares

This portal lets you subscribe to common shares of 1210954 B.C. Ltd. (PsilocybinLabs) on a private-placement basis. Funds flow to McMillan LLP, In Trust, per the wire instructions disclosed at the close of the subscription flow.

Subscriptions are accepted under one of three prospectus exemptions: Canadian Accredited Investor (NI 45-106 §2.3), Family, Friends & Business Associates (§2.5, ex-Ontario), or U.S. Accredited Investor (Reg D Rule 506(b)).

—Securities offered are subject to indefinite resale restrictions under Canadian securities laws. You may lose your entire investment.
—This is not a public offering. The Company is not a reporting issuer in any jurisdiction.
—Subscription is subject to acceptance by the Company's board and applicable regulatory clearance.
Deal economics · at-a-glance
As of today · Indicative
Issuer
1210954 B.C. Ltd. (PsilocybinLabs)
d/b/a PsilocybinLabs - $0.50 Share Offering
Security
Common share
No-par-value · voting
Unit price
$0.5CAD
Min 100 shares · CA$50
Round target
$3.0M CAD
Rolling close · uncapped
Pre-money
$8.5M CAD
Indicative · founder-set
Hold period
4mo+ 1d
NI 45-102 statutory
Use of Proceeds

Where capital is deployed

Indicative allocation across pre-clinical research, regulatory affairs, and operations through the next twelve months. Subject to board re-allocation as the program advances.

Pre-clinical R&DCompound & formulation
42%$1.26M
Regulatory & IPHealth Canada / FDA / patents
22%$660K
Clinical advisoryKOL retainers, study design
14%$420K
Operations & G&ASalaries, lab, admin
16%$480K
Working capitalReserves & offering costs
6%$180K
Offering Timeline

From subscription to issued certificate

✓
Step 01
Subscribe
Complete the 5-step subscription form and certify your exemption.
02
T + 0–1d
Execute
Counter-sign via DocuSign or wet-ink. Form 45-106F9 if AI individual.
03
T + 1–3d
Wire funds
Transfer to McMillan LLP, In Trust. KYC/AML verification runs in parallel.
04
T + 3–10d
Board accept
Board reviews and accepts the subscription, or returns funds.
05
T + 10d
Certificate
Shares issued to the register. 4-month-and-one-day hold begins.
Regulatory frameworkOperating under
NI 45-106· §2.3 AI
NI 45-106· §2.5 FFBA
Reg D· Rule 506(b)
NI 45-102· 4mo+1d hold
FINTRAC· KYC / AML
DocuSign· ESIGN / UECA
McMillan LLP· Trustee
Disclosures · terms & counsel
Read before subscribing
About

PsilocybinLabs - $0.50 Share Offering is conducting a private placement to fund early-stage research into therapeutic applications of psilocybin and related compounds, and to advance pre-clinical work toward Health Canada and FDA-recognized pathways.

The offering is being made on a non-prospectus basis to subscribers who qualify under one or more of the prospectus exemptions referenced above. Subscription proceeds are received by the Company's counsel, McMillan LLP, In Trust, until acceptance.

Closing

Subscriptions are accepted on a rolling basis until the offering closes. Acceptance is at the discretion of the Company's board and is contingent on:

  • Receipt of cleared funds at McMillan LLP, In Trust;
  • A fully executed Subscription Agreement and applicable schedules;
  • Form 45-106F9 risk acknowledgement (for individual Accredited Investor subscribers in categories (j), (j.1), (k), (l));
  • Any documentation reasonably requested for KYC/AML verification.

Securities issued are subject to a four-month-and-one-day hold under NI 45-102, and additional resale restrictions may apply.

Legal & Tax

This portal does not constitute legal, tax, or investment advice. Subscribers are encouraged to obtain independent legal, tax, and financial advice before subscribing.

Questions of legal interpretation: Sasa Jarvis at McMillan LLP. Issuer questions: Ian McDonald · ian@northwardcap.com · 1-647-407-2515.